These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 9154283)

  • 1. The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents.
    Hoyng PF; Rulo A; Greve E; Watson P; Alm A
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S93-8. PubMed ID: 9154283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy.
    Diestelhorst M; Nordmann JP; Toris CB
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S155-61. PubMed ID: 12204713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latanoprost and cholinergic agonists in combination.
    Toris CB; Alm A; Camras CB
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S141-7. PubMed ID: 12204711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group.
    Nordmann JP; Söderström M; Rouland JF; Malecaze F
    Br J Ophthalmol; 2000 Feb; 84(2):181-5. PubMed ID: 10655195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.
    Bucci MG
    J Glaucoma; 1999 Feb; 8(1):24-30. PubMed ID: 10084271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Latanoprost topical ophthalmic combinations].
    Călugăru M; Călugăru D
    Oftalmologia; 2004; 48(4):18-28. PubMed ID: 15782758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
    Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
    J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications.
    Higginbotham EJ; Diestelhorst M; Pfeiffer N; Rouland JF; Alm A
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S133-40. PubMed ID: 12204710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbead-induced ocular hypertensive mouse model for screening and testing of aqueous production suppressants for glaucoma.
    Yang Q; Cho KS; Chen H; Yu D; Wang WH; Luo G; Pang IH; Guo W; Chen DF
    Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):3733-41. PubMed ID: 22599582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandin derivates as ocular hypotensive agents.
    Alm A
    Prog Retin Eye Res; 1998 Jul; 17(3):291-312. PubMed ID: 9695796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
    García Sanchez J
    Eur J Ophthalmol; 2000; 10(3):198-204. PubMed ID: 11071026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies.
    Bayer A; Weiler W; Oeverhaus U; Skrotzki FE; Stewart WC;
    J Ocul Pharmacol Ther; 2004 Dec; 20(6):470-8. PubMed ID: 15684807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment.
    Greve EL; Rulo AH; Drance SM; Crichton AC; Mills RP; Hoyng PF
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S89-92. PubMed ID: 9154282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure.
    Rulo AH; Greve EL; Hoyng PF
    Ophthalmology; 1997 Sep; 104(9):1503-7. PubMed ID: 9307648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prospects of using latanoprost, prostaglandin F2 alpha analog, in hypotensive therapy for glaucoma].
    Egorov EA; Nesterov AP; Romanova OV
    Vestn Oftalmol; 1998; 114(4):19-20. PubMed ID: 9771080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of prostaglandin analogues in glaucoma.
    Lindén C
    Expert Opin Investig Drugs; 2001 Apr; 10(4):679-94. PubMed ID: 11281818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pilocarpine 4% in combination with latanoprost 0.005% or 8-iso prostaglandin E2 0.1% on intraocular pressure in laser-induced glaucomatous monkey eyes.
    Serle JB; Wang RF; Mittag TW; Shen F; Podos SM
    J Glaucoma; 2001 Jun; 10(3):215-9. PubMed ID: 11442186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of pilocarpine, timolol and latanoprost in experimental models of glaucoma.
    Gupta SK; Agarwal R; Galpalli ND; Srivastava S; Agrawal SS; Saxena R
    Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):665-71. PubMed ID: 18200329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension.A 3-month randomised study.
    Emmerich KH
    Graefes Arch Clin Exp Ophthalmol; 2000 Jan; 238(1):19-23. PubMed ID: 10664047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.